Hematological Malignancies

News alerts, weekly reports and conference planners

Related cancers:

‹

Leukemia (1997)

Lymphoma (1071)

Leukemia (1997)

Lymphoma (1071)

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval NCCN - 6 days (New A2) epcoritamab-bysp Sensitive : A1 NCCN - 6d	epcoritamab-bysp Sensitive: A1 - Approval NCCN - 6 days epcoritamab-bysp Sensitive : A1 NCCN - 6 days - (New A2)
KIT D816V	Chronic Myeloid Leukemia	KIT D816V	Chronic Myeloid Leukemia	acalabrutinib Sensitive: C4 – Case Studies Leuk Res - 6 days (New C4) acalabrutinib Sensitive : C4 Leuk Res - 6d	acalabrutinib Sensitive: C4 – Case Studies Leuk Res - 6 days acalabrutinib Sensitive : C4 Leuk Res - 6 days - (New C4)
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week (New A1) zanubrutinib Sensitive : A1 BeiGene Press Release - 1wk	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week zanubrutinib Sensitive : A1 BeiGene Press Release - 1 week - (New A1)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval Clin Cancer Res - 1 week (New C3) ivosidenib Sensitive : A1 Clin Cancer Res - 1wk	ivosidenib Sensitive: A1 - Approval Clin Cancer Res - 1 week ivosidenib Sensitive : A1 Clin Cancer Res - 1 week - (New C3)
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval Leuk Lymphoma - 1 week (New C3) brentuximab vedotin Sensitive : A1 Leuk Lymphoma - 1wk	brentuximab vedotin Sensitive: A1 - Approval Leuk Lymphoma - 1 week brentuximab vedotin Sensitive : A1 Leuk Lymphoma - 1 week - (New C3)
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2 weeks - (New C3)
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials Blood Cancer J - 2 weeks (New C3) lenalidomide Sensitive : B Blood Cancer J - 2wk	lenalidomide Sensitive: B - Late Trials Blood Cancer J - 2 weeks lenalidomide Sensitive : B Blood Cancer J - 2 weeks - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval ASCO 2023 - 2 weeks (New C3) olutasidenib Sensitive : A1 ASCO 2023 - 2wk	olutasidenib Sensitive: A1 - Approval ASCO 2023 - 2 weeks olutasidenib Sensitive : A1 ASCO 2023 - 2 weeks - (New C3)
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval ASCO 2023 - 2 weeks (New C3) inotuzumab ozogamicin Sensitive : A1 ASCO 2023 - 2wk	inotuzumab ozogamicin Sensitive: A1 - Approval ASCO 2023 - 2 weeks inotuzumab ozogamicin Sensitive : A1 ASCO 2023 - 2 weeks - (New C3)
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : A1 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: A1 - Approval ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : A1 ASCO 2023 - 2 weeks - (New C3)
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax Sensitive: A2 - Guideline ASCO 2023 - 2 weeks (New C3) venetoclax Sensitive : A2 ASCO 2023 - 2wk	venetoclax Sensitive: A2 - Guideline ASCO 2023 - 2 weeks venetoclax Sensitive : A2 ASCO 2023 - 2 weeks - (New C3)
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: A2 - Guideline ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : A2 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: B - Late Trials ASCO 2023 - 2 weeks (New C3) venetoclax Resistant : B ASCO 2023 - 2wk	venetoclax Resistant: B - Late Trials ASCO 2023 - 2 weeks venetoclax Resistant : B ASCO 2023 - 2 weeks - (New C3)
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials ASCO 2023 - 2 weeks (New C3) venetoclax Sensitive : B ASCO 2023 - 2wk	venetoclax Sensitive: B - Late Trials ASCO 2023 - 2 weeks venetoclax Sensitive : B ASCO 2023 - 2 weeks - (New C3)
Chr del(17p)	Acute Myelogenous Leukemia	Chr del(17p)	Acute Myelogenous Leukemia	venetoclax Sensitive: C1 - Off-label ASCO 2023 - 2 weeks (New C3) venetoclax Sensitive : C1 ASCO 2023 - 2wk	venetoclax Sensitive: C1 - Off-label ASCO 2023 - 2 weeks venetoclax Sensitive : C1 ASCO 2023 - 2 weeks - (New C3)
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks (New C3) epcoritamab-bysp Sensitive : C2 ASCO 2023 - 2wk	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks epcoritamab-bysp Sensitive : C2 ASCO 2023 - 2 weeks - (New C3)
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks (New C3) blinatumomab + inotuzumab ozogamicin Sensitive : C2 ASCO 2023 - 2wk	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks blinatumomab + inotuzumab ozogamicin Sensitive : C2 ASCO 2023 - 2 weeks - (New C3)
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	IMM0306 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks (New C3) IMM0306 Sensitive : C2 ASCO 2023 - 2wk	IMM0306 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks IMM0306 Sensitive : C2 ASCO 2023 - 2 weeks - (New C3)
CCR4 positive	Leukemia	CCR4 positive	Leukemia	mogamulizumab Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks (New C3) mogamulizumab Sensitive : C2 ASCO 2023 - 2wk	mogamulizumab Sensitive: C2 – Inclusion Criteria ASCO 2023 - 2 weeks mogamulizumab Sensitive : C2 ASCO 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) venetoclax + gilteritinib Sensitive : C3 ASCO 2023 - 2wk	venetoclax + gilteritinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks venetoclax + gilteritinib Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) ponatinib + blinatumomab Sensitive : C3 ASCO 2023 - 2wk	ponatinib + blinatumomab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks ponatinib + blinatumomab Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) lintuzumab-Ac225 Sensitive : C3 ASCO 2023 - 2wk	lintuzumab-Ac225 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks lintuzumab-Ac225 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
Chr t(11;14) + Chr amplification(1q)	Multiple Myeloma	Chr t(11;14) + Chr amplification(1q)	Multiple Myeloma	venetoclax Resistant: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) venetoclax Resistant : C3 ASCO 2023 - 2wk	venetoclax Resistant: C3 – Early Trials ASCO 2023 - 2 weeks venetoclax Resistant : C3 ASCO 2023 - 2 weeks - (New C3)
IL6-L	Multiple Myeloma	IL6-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TNFRSF17 amplification	Multiple Myeloma	TNFRSF17 amplification	Multiple Myeloma	PF-06863135 Resistant: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Resistant : C3 ASCO 2023 - 2wk	PF-06863135 Resistant: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Resistant : C3 ASCO 2023 - 2 weeks - (New C3)
CCL3-L	Multiple Myeloma	CCL3-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
IL17C-L	Multiple Myeloma	IL17C-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) pirtobrutinib Sensitive : C3 ASCO 2023 - 2wk	pirtobrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks pirtobrutinib Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
CD20 positive	Marginal Zone Lymphoma	CD20 positive	Marginal Zone Lymphoma	IMM0306 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) IMM0306 Sensitive : C3 ASCO 2023 - 2wk	IMM0306 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks IMM0306 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	GC012F Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) GC012F Sensitive : C3 ASCO 2023 - 2wk	GC012F Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks GC012F Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
PD-L1 expression	Hodgkin Lymphoma	PD-L1 expression	Hodgkin Lymphoma	sintilimab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) sintilimab Sensitive : C3 ASCO 2023 - 2wk	sintilimab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks sintilimab Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	FLAG-IDA Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) FLAG-IDA Sensitive : C3 ASCO 2023 - 2wk	FLAG-IDA Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks FLAG-IDA Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
Chr del(17p)	Acute Myelogenous Leukemia	Chr del(17p)	Acute Myelogenous Leukemia	FLAG-IDA Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) FLAG-IDA Sensitive : C3 ASCO 2023 - 2wk	FLAG-IDA Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks FLAG-IDA Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : C3 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) venetoclax + ibrutinib Sensitive : C3 ASCO 2023 - 2wk	venetoclax + ibrutinib Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks venetoclax + ibrutinib Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion negative	Acute Lymphocytic Leukemia	BCR-ABL1 fusion negative	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) blinatumomab + inotuzumab ozogamicin Sensitive : C3 ASCO 2023 - 2wk	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks blinatumomab + inotuzumab ozogamicin Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion negative	Acute Lymphocytic Leukemia	BCR-ABL1 fusion negative	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) inotuzumab ozogamicin Sensitive : C3 ASCO 2023 - 2wk	inotuzumab ozogamicin Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks inotuzumab ozogamicin Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	DAV Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) DAV Sensitive : C3 ASCO 2023 - 2wk	DAV Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks DAV Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 ASCO 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks PF-06863135 Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	IDH1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) IDH1 inhibitor Sensitive : C3 ASCO 2023 - 2wk	IDH1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks IDH1 inhibitor Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	IDH1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) IDH1 inhibitor Sensitive : C3 ASCO 2023 - 2wk	IDH1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks IDH1 inhibitor Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
BRAF mutation + TET2 mutation	Acute Myelogenous Leukemia	BRAF mutation + TET2 mutation	Acute Myelogenous Leukemia	MLN4924 + belinostat Sensitive: C4 – Case Studies ASCO 2023 - 2 weeks (New C4) MLN4924 + belinostat Sensitive : C4 ASCO 2023 - 2wk	MLN4924 + belinostat Sensitive: C4 – Case Studies ASCO 2023 - 2 weeks MLN4924 + belinostat Sensitive : C4 ASCO 2023 - 2 weeks - (New C4)
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	Sensitive: D – Preclinical ASCO 2023 - 2 weeks (New D) Sensitive : D ASCO 2023 - 2wk	Sensitive: D – Preclinical ASCO 2023 - 2 weeks Sensitive : D ASCO 2023 - 2 weeks - (New D)
MERTK expression	Multiple Myeloma	MERTK expression	Multiple Myeloma	RGX-019 Sensitive: D – Preclinical ASCO 2023 - 2 weeks (New D) RGX-019 Sensitive : D ASCO 2023 - 2wk	RGX-019 Sensitive: D – Preclinical ASCO 2023 - 2 weeks RGX-019 Sensitive : D ASCO 2023 - 2 weeks - (New D)
MERTK expression	Acute Myelogenous Leukemia	MERTK expression	Acute Myelogenous Leukemia	RGX-019 Sensitive: D – Preclinical ASCO 2023 - 2 weeks (New D) RGX-019 Sensitive : D ASCO 2023 - 2wk	RGX-019 Sensitive: D – Preclinical ASCO 2023 - 2 weeks RGX-019 Sensitive : D ASCO 2023 - 2 weeks - (New D)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 3 weeks (New B) IMPT-314 Sensitive : B PRNewswire - 3wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 3 weeks IMPT-314 Sensitive : B PRNewswire - 3 weeks - (New B)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 3 weeks (New B) IMPT-314 Sensitive : B PRNewswire - 3wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 3 weeks IMPT-314 Sensitive : B PRNewswire - 3 weeks - (New B)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Lymphoma	No biomarker	Lymphoma	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	SVd Sensitive: A1 - Approval SVd Sensitive : A1	SVd Sensitive: A1 - Approval SVd Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1

Hematological Malignancies

Associations(3593)

Associations
(3593)